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Available online 26 August 2016Introduction: Hypophosphatasia, a metabolic bone disease caused by a tissue-nonspeciﬁc alkaline phosphatase
deﬁciency, leads to undermineralization of bone and/or teeth, impaired vitamin B6 metabolism, and a spectrum
of disease presentation. At the mild end of the spectrum, it presents as pathologic fractures in later adulthood.
Patients with isolated dental manifestations, typically presenting as premature loss of primary teeth, are classi-
ﬁed as having odontohypophosphatasia (odontoHPP). A subset of patients diagnosed with odontoHPP in child-
hood can later develop extra-dental manifestations that constitute childhood- or adult-onset hypophosphatasia.
Case reports: methods/results: Retrospective data related to onset, detailed clinical course, and method of diagno-
sis were collected as part of a natural history of adult patients with hypophosphatasia.
Of 9 initial patients, all had low serum alkaline phosphatase levels for their age and gender at adult presentation
(Table 2). The majority (8/9) demonstrated childhood dental signs of hypophosphatasia as the initial clinical
manifestation: premature loss of primary teeth (7/9), absent primary teeth (1/9), and delayed loss of primary
teeth (1/9). Despite childhood dental presentation and/or other signs/symptoms, diagnosis of hypophosphatasia
was delayed 20–54 years (median= 46) since the primary tooth problems and 8–45 years (median= 27) since
the ﬁrst fracture or onset of a major adult tooth problem.
Conclusion: Patients with primary tooth loss in childhood were often diagnosed with hypophosphatasia later in
life. Pediatric patients classiﬁed as having odontoHPPunder present practice canmanifest signiﬁcant disease bur-
den later in life.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Tissue-nonspeciﬁc alkaline phosphatase1. Introduction
Hypophosphatasia (HPP) is a heritable metabolic bone disease char-
acterized by defective bone mineralization and complications
(Hofmann et al., 2013) due to deﬁciency of tissue-nonspeciﬁc alkaline
phosphatase (TNSALP), 1 of the 3 alkaline phosphatase isoforms
(Hofmann et al., 2013; Whyte, 2012; Rockman-Greenberg, 2013). At
least 300 distinct mutations of the TNSALP gene (ALPL; Genbank acces-
sion number NG_008940.1) have been identiﬁed to cause HPP in differ-
ent populations from various ethnic backgrounds, in either autosomal
dominant or autosomal recessive fashion (Mornet, 2015). The TNSALP
deﬁciency is also reﬂected in a low serum total alkaline phosphatase
(ALP) level. SerumALPmeasurement is readily available inmost clinical1, 4th Floor, Room 4010, 905 S.
hanie.dearmey@duke.edu
riya.kishnani@duke.edu
. This is an open access article undersettings and is a sensitive screening test for HPP in the setting of clinical
history consistent with the disease. As physiological ALP is normally
higher in childhood, it is critical that an age- and gender-speciﬁc refer-
ence range is used for its interpretation (Mornet and Nunes, 2016).
Other conditions that can cause low ALP include hypothyroidism, mul-
tiple myeloma, Cushing's syndrome, profound anemia, and vitamin D
intoxication (Whyte, 2013). These conditions can be differentiated by
clinical history and additional laboratory tests. TNSALP deﬁciency also
leads to elevated concentrations of some substrates in urine and plasma,
which can be used as diagnostic markers. These biomarkers include in-
organic pyrophosphate (PPi) (Buchet et al., 2013), pyridoxal-5′-phos-
phate (PLP), the predominant circulating form of vitamin B6 (Coburn
and Whyte, 1988), and phosphoethanolamine. Elevated extracellular
levels of PPi inhibit bone mineralization by blocking hydroxyapatite
crystal growth (Millán and Plotkin, 2012). In severe cases, PLP cannot
sufﬁciently be dephosphorylated to pyridoxal by TNSALP in order to
cross the blood-brain barrier and function as a cofactor in neurotrans-
mitter biosynthesis, which may cause vitamin B6-responsive seizures
(Baumgartner-Sigl et al., 2007; Buchet et al., 2013; Waymire et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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deformity of bones, osteomalacia, premature loss of teeth, and dental
caries, as well as failure to thrive, craniosynostosis, seizures,
nephrocalcinosis, and respiratory compromise due to rachitic chest in
severe forms (Rockman-Greenberg, 2013).
HPP shows considerable expressive variability, with highest mortal-
ity risk in patientswith onset of signs or symptoms in utero or during in-
fancy, and non-lethal disease burden in patients with later disease
manifestation (Rockman-Greenberg, 2013; Whyte et al., 1979; Whyte
et al., 1982). HPP has been historically classiﬁed according to the pres-
ence/absence of bone disease and the age of ﬁrst appearance of clinical
manifestation(s): perinatal (onset in utero and generally lethal), infan-
tile (onset prior to 6 months of age and associated with approximately
50% mortality due to respiratory failure), childhood (onset from
6 months to 18 years inclusive), or adult (onset after 18 years of age)
(Rockman-Greenberg, 2013; Whyte, 2013; Mornet and Nunes, 2016).
However, substantial clinical overlap among the identiﬁed phenotypes
can occur (Hofmann et al., 2013). Odontohypophosphatasia
(odontoHPP) is characterized by isolated dental symptoms in the ab-
sence of skeletal abnormalities (Rockman-Greenberg, 2013; Whyte,
2013). Diagnosis of odontoHPP is made when dental disease is the
only physical manifestation accompanying the biochemical characteris-
tics of HPP. Therefore, additional diagnostic radiological studies and
bone biopsies, if needed, should be done to rule out evidence of rickets
or osteomalacia (Millán and Plotkin, 2012;Whyte et al., 2015). The den-
tal abnormalities frequently observed include abnormal formation of
cementum, enamel, increased pulp spaces, and premature loss of fully
rooted primary teeth before the age of 5 years and often adult teeth
(Beck et al., 2009; Hartsﬁeld, 1994).
Adult-onset HPP is typically diagnosed upon the presentation of
skeletal symptoms in middle age. Frequently, however, these patients
recollect unusual early childhood tooth loss (Whyte, 2013) or their par-
ents' accounts of it, or have a childhood history of fractures or chronic
muscle pain. When dental symptoms appear early in life in the absence
of skeletal disease, a diagnosis of odontoHPP may seem appropriate at
the time, but a subset of affected patients may later develop signs of
childhood/adult-onset HPP. These patients and their families require
appropriate education and periodic follow-up for bone and other sec-
ondary complications. In light of the recent approval of enzyme replace-
ment therapy with recombinant human TNSALP, this population may
potentially beneﬁt from early diagnosis and early treatment.
Berkseth and colleagues (Berkseth et al., 2013) performed a retro-
spective medical record review of 22 adults with HPP. However, the
study was limited due to its method of medical record review. It is pos-
sible that a childhood dental history was under-recognized. Here, we
describe our experience with the ﬁrst 9 patients in our HPP natural his-
tory study who were diagnosed with HPP in adulthood. The majority
had dental manifestations in childhood, such as premature tooth loss,
persistent primary teeth, or absent primary teeth, and later developed
chronic muscle/joint pain and recurrent pathological fractures. Most of
these patients remained undiagnosed despite evaluation by multiple
specialists. Our study illustrates the importance of HPP as a differential
diagnosis in patients with primary tooth problems in the setting of
low serum total ALP for age and gender, as well as their long-term fol-
low-up.
2. Case reports: methods and results
We collected retrospective clinical data related to the onset of HPP in
our patients, its detailed clinical course, and method of HPP diagnosis
through patient interview andmedical record review. Biochemical ana-
lytical assessments were conducted by Covance Inc., 8211 SciCor Drive,
Indianapolis, IN 46214, USA. PLP analysiswas performed at either ARUP,
500 Chipeta Way, Salt Lake City, UT 84108, USA or Biotrial Bioanalytical
Services, Inc., 3885 boul. Industriel, Laval, Quebec, Canada, H7L 4S3.
Gene mutation analysis was conducted by Connective Tissue GeneTests (CTGT), 6580 Snowdrift Road, Suite 300, Allentown, PA 18106,
USA.
2.1. Compliance with ethical guidelines
Our natural history study was approved by the Duke University
Health System Institutional Review Board under protocol
Pro00024134 and is registered in ClinicalTrials.gov (NCT02237625).
The authors obtained patient consent to report their clinical data. Retro-
spective medical histories obtained at enrollment are reported here.
2.2. Case report ﬁndings
2.2.1. Case 1
This patient was a 35-year-old man who required extraction of pri-
mary teeth because they would not spontaneously exfoliate and devel-
oped an inability to sit on the ground, due to discomfort in childhood;
chronic back and foot pain; and shattering of a molar tooth at age 25.
Dentists reported his teeth were translucent with microfractures. He
was diagnosed with HPP based on low ALP level, clinical history, and a
heterozygous mutation in ALPL.
2.2.2. Case 2
This 71-year-old woman had developed a total of 21 fractures
starting at age 26, and at age 53 was diagnosed with HPP by a rheuma-
tologist. She had experienced loss of adult teeth and a tooth abscess re-
quiring root canal surgery.
2.2.3. Case 3
This is a 32-year-oldmanwho lost all of his primary teeth soon after
their eruption, was noted to have bowed tibia in childhood, and was di-
agnosedwith childhoodHPP at age 3 based on this history and lowALP.
He later developed repeated stress fractures of the third metatarsals
after intense military training. He lost an adult maxillary incisor tooth
after biting into a piece of meat and hitting bone unexpectedly. His den-
tal bridge required support by multiple contiguous teeth due to loose
anchoring of the adjacent tooth.
2.2.4. Case 4
The patient was a 58-year-old woman who had premature primary
tooth loss at age 3. Starting at age 14, she had experienced a total of 7
fractures and delayed healing of the fractured bones, as well as progres-
sive musculoskeletal pain in her late 40s.
2.2.5. Case 5
This is a 62-year-old woman who lost all her front primary teeth at
age 13 months, and developed 7 fractures starting at age 8. A bone
scan at age 55 showed marked degenerative changes in both hands
and both feet, as well as abnormal radiotracer uptake in the mid-left
third metatarsal suggestive of a stress fracture.
2.2.6. Case 6
This 63-year-old woman is the sister of Case 7. She had premature
loss of primary teeth at age 3, developed chronic joint pains in her
teens, lost an adult tooth at age 18, and experienced her ﬁrst fracture
at age 19 after a fall. She had a total of 9 fractures throughout her life,
which took longer than expected to heal. An endocrinologist diagnosed
her with HPP at age 57.
2.2.7. Case 7
This is a 50-year-old woman who had missing teeth and premature
primary tooth loss, developed chronic joint pain and required orthope-
dic shoes in childhood, and developed 19 fractures starting at age 18.
She was evaluated by an endocrinologist for osteoporosis refractory to
medical therapy and multiple fractures, and radioiodine ablation was
performed due to suspected hyperthyroidism as an underlying cause.
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HPP was made by another endocrinologist based on a low ALP value
andwas genetically conﬁrmedwith compoundheterozygousmutations
of ALPL.
2.2.8. Case 8
This is a 60-year-old womanwho had premature primary tooth loss
at age 3. While her ﬁrst fracture occurred at age 12 in her collar bone,
she had a relatively healthy adult life until age 42 when she started to
have more fractures, went on to develop approximately 25 of them,
and also suffered from chronic joint pain. A whole-body scan at age
55, after her menopause, showed evidence of numerous fractures at
various healing stages, including fractures of both femurs, both feet,
the right ulna, and the left wrist. The diagnosiswasmade by an endocri-
nologist based on her clinical history and low ALP.
2.2.9. Case 9
This is a 59-year-old woman who lost her primary teeth at ages 3 to
4 years andwas subsequently diagnosedwith HPP based on history and
low ALP by a dentist. She had clubfoot deformity in infancy and experi-
enced 6 fractures starting at age 6 years. A right knee MRI at age 41
showed ﬁndings of chondromalacia, with thinning of the articular carti-
lage over both femoral condyles.
2.3. Summary of cases
Nine adults with HPP are described (7 women, 2 men), with ages
ranging from 33 to 70 years; the median age at HPP diagnosis was
41 years (range, 3–57 years). Summaries of key patient characteristics,
includingALPL genotypes, are provided in Table 1. Eight out of 9 patients
had demonstrated dental manifestations of the disease in childhood; 7
experienced premature loss of primary teeth at ages ranging from
8months to 4 years (Cases 3–9); 1 had persistence of primary teeth re-
quiring extraction (Case 1; estimated 8 years of age at teeth removal);
and 1 had absence of some primary teeth (Case 7). Despite the child-
hood dental presentation with or without pathological fractures, as
well as evaluation by multiple specialists, the delay in diagnosis of
HPP following childhood dental problems ranged from 20 years (Case
4) to 54 years (Case 6),with amedian of 46 years in the affected patients
(Cases 1, 4–8) (not shown in Table 1). The diagnosis of HPPwas also de-
layed since the ﬁrst fracture or onset of major adult tooth problems in 7
patients (Cases 1, 2, 4, 5, 6, 7 and 8), ranging from 8 years (Case 1 esti-
mate) to 45 years (Case 5), with a median of 27 years; only 2 patients
(Cases 3 and 9) were diagnosed with HPP shortly after tooth loss. All 9
patients had complaints of chronic muscle/joint pain affecting their
quality of life, either since childhood or young adulthood. Eight patients
had recurrent pathological fractures, ranging in number from 2 to 25
fractures, with amedian of 8 fractures to date. Five patients experienced
bone fractures during childhood (Cases 3, 4, 5, 8, and 9) at ages 17, 14, 8,
12, and 6 years, respectively. The remaining 4 did not report bone frac-
tures during childhood, but 2 showed other symptoms that might be
considered suggestive of HPP, such as chronic joint pain and foot defor-
mity (Cases 1 and 7). Four patients (Cases 6–9)were compound hetero-
zygotes for ALPL gene mutations. Chemistry values for 25-hydroxy
vitamin D (25-OH vitD), calcium, parathyroid hormone, and phospho-
rus were generally within the reference ranges, with few exceptions
(e.g., elevated 25-OH vitD in Case 2). PLP was elevated in all patients.
All reviewed cases had low serum ALP levels, near or below the lower
limit of the adult reference range (Table 2).
3. Discussion and conclusion
Findings from our case series suggest that patients with an isolated
dental manifestation of HPP in childhood may later develop the adult
or childhood forms of the disease. Therefore, odontoHPP may well be
more appropriately characterized as a disease manifestation of patientswithHPP during their childhood rather than as a discrete diagnostic cat-
egory in cases when premature tooth loss is the primary manifestation.
It should be noted that there is a subset of patients with premature
tooth loss who do not go on to develop other bone manifestations of
HPP and are thus likely true odontoHPP patients, as deﬁned in the liter-
ature. Most (8/9) of the patients in this case series showed clear signs of
early deﬁcits in dental health during early childhood between ages
8 months and 4 years. The pathology of persistent primary teeth in
Case 1was not made clear andmay ormay not be due to his HPP.With-
out additional gross evidence of skeletal abnormalities, the other 8 sub-
jects appeared to have met the dental criteria for odontoHPP until
additional bone-related pathologiesmanifestedmuch later in life. Inter-
estingly, at the initial dental presentation,most of them (6/8) did not re-
ceive an odontoHPP or HPP diagnosis. Increased awareness of the early
disease presentation of HPP among dental and primary care providers is
warranted. More has to be learned to permit distinguishing those pa-
tients who have premature loss of primary teeth as the discrete diag-
nostic category from those where this tooth loss is an initial
manifestation of signs and symptoms of HPP. Low total ALP in the set-
ting of a clinical history of dental issues and/or skeletal manifestations
is strongly suggestive of HPP.
Our study also demonstrates signiﬁcant disease burden in these pa-
tients with what was thought to be a mild form of HPP, with many of
them suffering frequent fractures, chronic pain, restrictive life style,
and depression due to chronic pain and fear of sustaining pathological
fractures. Eight of the 9 patients did in retrospect manifest non-dental
signs/symptoms in childhood such as skeletal deformity and fractures,
and all suffered from chronic muscle pain and depression (personal ob-
servations). Notably, nearly all (8/9) patients experienced fractures, ei-
ther starting in childhood between the ages of 6 and 17 years (Cases 3–
5, 8, and 9) or in adulthood (≥18 years old) (Cases 2, 6, and 7).
In our series, the diagnosis of HPP was often signiﬁcantly delayed
(median of 46 years since the initial dental presentation and 27 years
since the ﬁrst fracture/major adult tooth problem) despite low ALP
levels or a substantial disease burden often starting in childhood. The
early diagnosis and appropriate follow-up of these patients, starting
from the initial presentation in childhood and continuing into adult-
hood, is important so that other symptoms of HPP can be identiﬁed
and treated at their earliest presentation. Bone-targeted enzyme re-
placement therapywith asfotase alfa (ahuman recombinant TNSALP fu-
sion protein) has shownpromising results in infants and young children
(Whyte et al., 2012), and is now approved as therapy inmany countries
worldwide (currently approved for perinatal/infantile/childhood-onset
forms in the United States, Canada, and European Union; and for all cat-
egories of HPP in Japan). Clinical trials for adolescent and adult HPP are
underway (NCT01163149; NCT00739505). Early diagnosis could offer
patients the opportunity to beneﬁt from this therapy as it becomes
widely available.
The strength of this study is the post-HPP diagnosis interview pro-
cess, which facilitated targeted medical history elicitation in regard to
skeletal and dental events. The study is limited by its observational
case-based nature and the absence of a control group.
Patients with premature primary tooth loss or signiﬁcant dental ab-
normalities in the setting of low ALP for age should be evaluated for a
diagnosis of HPP. These patients should be followed closely for other
manifestations of HPP, including developmental delay, hypotonia, skel-
etal abnormalities, hypercalcemia, chronic pain/fatigue, and patho-
logical fractures. Patients presenting with apparently isolated
dental symptoms should be monitored for the emergence of bone
or systemic symptoms during the remainder of childhood and
throughout adulthood. Based on our observations, we would pro-
pose that the term odontohypophosphatasia should be used to de-
scribe the dental manifestation(s) of the disease and that its use as
a diagnostic category should be reserved until much later in life
when extra-dental manifestations have not become evident after
long-term follow-up.
Table 1
Key characteristics of 9 adult patients with HPP.
Case Age
(y)/gender
Early dental
issues
Age of
ﬁrst
fracture
(y)
Fractures
(no.)
Other bone
issues
Other disease burden Genotypea Inheritance Family history of HPP Diagnosing
specialty
Age at
diagnosis
(y)
1 35/male Persistent
primary teeth,
requiring
extraction
No
fractures
0 Chronic back
pain; bone pain
Chronic fatigue; difﬁculty sleeping,
joint pain
c.335_340dupACCGCC
(p.Gly112_Thr113dup2)
in exon 5
AD Sister and niece: c.335_340dupACCGCC
(p.Gly112_Thr113dup2). Father and paternal
uncle with symptoms without conﬁrmed
diagnosis
Unknown 33, due to
positive
family
history
2 70/female No dental
complaints
26 21 Delayed
healing of
fractures; bone
pain
Feeding difﬁculty c.1328C N T (p.A443V)
in exon 12
AD Unknown Rheumatology 53
3 32/male Loss of all
primary teeth
starting at 8
months
17 2 – Unusual gait c.1133A N T (p.D378V)
in exon 10
AD Asymptomatic 2-year-old son: conﬁrmed
familial mutation. Mother, sister, brother, and a
maternal aunt with symptoms without
diagnosis. Conﬁrmed HPP
Endocrinology 3
4 58/female Primary tooth
loss at age 3
years
14 7 Bone pain;
abnormally
shaped head;
genu valgum
Unusual gait; delayed talking;
muscle pain and weakness; joint
pain and swelling
c.1133A N T (p.D378V)
in exon 10
AD Niece: prenatally diagnosed HPP. Son of a
different niece: conﬁrmed HPP
Endocrinology 23, due to
positive
family
history
5 62/female Loss of all front
primary teeth at
13 months
8 7 Bone pain Unusual gait c.1133A N T (p.D378V)
in exon 10
AD Son and granddaughter through the son:
conﬁrmed HPP
Unknown 53
6 63/female Primary tooth
loss at age 3
years
19 9 Bone pain Difﬁculty eating/swallowing c.526G N A (p.A176T) in
exon 6/c.648 + 1G N A
in IVS6
AR Sister (Case 7): conﬁrmed with HPP Endocrinology 57
7 50/female Primary tooth
loss before age
2; absent
primary teeth
18 19 Bone pain Unusual gait; joint pain/swelling;
long QT; hypokalemia
c.526G N A (p.A176T) in
exon 6/c.648 + 1G N A
in IVS6
AR Sister (Case 6): extractions of all of her teeth;
metatarsal stress fractures
Endocrinology 41
8 60/female Primary tooth
loss at age 3
years
12 25 Bone pain Unusual gait; joint hypermobility;
joint dislocation/pain; muscle
pain/weakness, carpal tunnel
surgery, pneumonia
c.571G N A (p.E191K) in
exon 6/c.661G N C
(p.G221R) in exon 7
AR Brother: premature tooth loss Endocrinology 55
9 59/female Primary tooth
loss at 3–4 years
6 6 Club foot; bone
pain
Unusual gait; gout c.571G N A (p.E191K) in
exon 6/c.1250A N G
(p.N417S) in exon 11
AR Unknown Unknown 4
AD, autosomal dominant; AR, autosomal recessive.
a Mutations shown are to the ALPL gene; Genbank accession number NG_008940.1.
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Table 2
Clinical chemistry values in patients with HPP.
Patient ID Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Age (y)/M or F 35 M 70 F 32 M 58 F 62 F 63 F 50 F 60 F 59 F
Calcium [8.3–10.6 mg/dL] 9.6 10.2 9.8 10.1 10.3 10.0 9.6 10.4 10.0
Phosphorus [2.2–5.1 mg/dL] 4.4 5 5.1 5.1 4.8 5.5 5.1 5.4 4.5
Alk Phosa 17 b18 20 b18 33 24 b18 b18 b18
PTH [11–72 pg/mL] 25 19 nm 31 34 33 42 35 24
25-OH vitD [12–50 ng/mL] 24 67.4 20 47.2 34 37 32.9 31.1 27.6
PLP [5–50 ng/mL] 112 577 163 90.3 249.5 474 508 267 288.8
Alk phos, alkaline phosphatase; F, female; M, male; PTH, parathyroid hormone; 25-OH vitD, 25-hydroxy vitamin D; PLP, pyridoxal-5′-phosphate; nm, not measured; y, years. Values in
brackets [] are reference ranges.
a Alk phos reference ranges: women, 50–70 y: 35–123 U/L; men, 18–50 y: 31–129 U/L.
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